Patent Assignment
Reel/Frame 074485/0651
Security Interest
Recorded: 2026-01-23
Pages: 16
Assignor
BIOCRYST PHARMACEUTICALS, INC.
Executed: 2026-01-23
Assignee
WILMINGTON TRUST, NATIONAL ASSOCIATION
50 SOUTH SIXTH STREET, SUITE 1290, MINNEAPOLIS, MINNESOTA, 55402
Covered Properties
(76)
Bicyclic Heteroaromatic Inhibitors of KLK5
Application:
18/286,615 →
Publication:
US US20240239752A1
Crystalline Salts of a Plasma Kallikrein Inhibitor
Application:
19/224,669 →
Publication:
US US20250388545A1
Crystalline Salts of a Plasma Kallikrein Inhibitor
Crystalline Salts of a Plasma Kallikrein Inhibitor
Crystalline Salts of a Plasma Kallikrein Inhibitor
Crystalline Salts of a Plasma Kallikrein Inhibitor
Crystalline Salts of a Plasma Kallikrein Inhibitor
Crystalline Salts of a Plasma Kallikrein Inhibitor
Dosing Regimens for Oral ALK2 Kinase Inhibitors
Application:
18/268,688 →
Publication:
US US20240408096A1
Dosing Regimens for Oral Complement Factor D Inhibitors
Application:
17/630,692 →
Publication:
US US20220257556A1
Fusion Protein Inhibitors of KLK5
Application:
18/996,497 →
Publication:
US US20260028389A1
Human Plasma Kallikrein Inhibitors
Application:
18/894,797 →
Publication:
US US20250257040A1
Human Plasma Kallikrein Inhibitors
Application:
18/913,643 →
Publication:
US US20250270171A1
Imidazole-Containing Inhibitors of ALK2 Kinase
Application:
18/562,115 →
Publication:
US US20240270750A1
Imidazole-Containing Inhibitors of ALK2 Kinase
Application:
18/647,310 →
Publication:
US US20240376117A1
Oral Complement Factor D Inhibitors
Oral Complement Factor D Inhibitors
Application:
19/436,346 →
Publication:
US US20260165999A1
Oral Complement Factor D Inhibitors
Application:
17/767,798 →
Publication:
US US20250275991A1
Oral Dosage Forms and Oral Dosing Regimens for Treatment of Complement Mediated Diseases
Application:
19/145,363 →
Plasma Kallikrein Inhibitors and Methods of Use Thereof in Ocular Disorders
Pyrrolopyrimidine Amines as Complement Inhibitors
Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors
Application:
18/407,053 →
Publication:
US US20240294494A1
Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors
Application:
19/412,163 →
Publication:
US US20260092045A1
Synthesis of an Antiviral Azasugar Triphosphate
Anti-Influenza Compositions and Methods
Antiviral Nucleoside Analogs
Antiviral Treatments
Antiviral Treatments
Antiviral Treatments
Antiviral Treatments
Antiviral Treatments
Aza Nucleosides, Preparation Thereof and Use as Inhibitors of Rna Viral Polymerases
Benzopyrazole Compounds and Analogues Thereof
Compositions and Uses of Amidine Derivatives
Crystalline Salts of a Plasma Kallikrein Inhibitor
Crystalline Salts of a Plasma Kallikrein Inhibitor
Crystalline Salts of a Plasma Kallikrein Inhibitor
Crystalline Salts of a Plasma Kallikrein Inhibitor
Hepatitis C Therapies
Hepatitis C Therapies
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Human Plasma Kallikrein Inhibitors
Imidazole-Containing Inhibitors of ALK2 Kinase
Imidazole-Containing Inhibitors of ALK2 Kinase
Indole Compounds and Analogues Thereof
Methods for the Preparation of 9-Deazapurine Derivatives
Methods of Treating Hematologic Cancers
Process-Scale Synthesis of a Plasma Kallikrein Inhibitor
Prodrugs of Kallikrein Inhibitors
Prodrugs of Kallikrein Inhibitors
Pyrrolo [2,3-D}Pyrimidine Compounds and Analogues Thereof
Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors
Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors
Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors
Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors
Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors
Tetrahydrofuro [3,4-D] Dioxolane Compounds for Use in the Treatment of Viral Infections and Cancer
Therapeutic Furopyrimidines and Thienopyrimidines
Useful Pharmaceutical Salts of 7- [(3R, 4R) - 3 - Hydroxy -4 - Hydroxymethyl - Pyrrolidin -1- Ylmethyl] -3, 5-Dihydro-Pyrrolo [3, 2-D] Pyrimidin -4-One
Anti-C2 Binding Agents and Conjugates Thereof
PCT:
PCT/US2024/054068 ↗
Bifunctional Therapeutic Antibody Targeting the Complement Cascade
PCT:
PCT/US2025/053503 ↗
Tricyclic Heteroaromatic Inhibitors of KLK5
PCT:
PCT/US2024/043684 ↗
Use of Avoralstat in the Treatment of Diabetic Macular Edema and Related Ocular Diseases
PCT:
PCT/US2026/010780 ↗
Related Assignments
(19)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Mar 29, 2022
From: BABU, YARLAGADDA S.; SHERIDAN, WILLIAM P.
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 059421/0725 →
Assignment of Assignor's Interest
Aug 9, 2022
From: KOTIAN, PRAVIN L; BABU, YARLAGADDA S; ZHANG, WEIHI; LU, PENG-CHENG
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 060757/0540 →
Assignment of Assignor's Interest
Aug 9, 2022
From: KOTIAN, PRAVIN L; BABU, YARLAGADDA S; ZHANG, WEIHE; LU, PENG-CHENG
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 060754/0703 →
Assignment of Assignor's Interest
Jan 26, 2023
From: KOTIAN, PRAVIN L.; BABU, YARLAGADDA S.; WU, MINWAN; DANG, ZHAO
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 062491/0466 →
Security Interest
Apr 18, 2023
From: BIOCRYST PHARMACEUTICALS, INC.
To: ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
Reel/Frame 063359/0174 →
Release of Security Interest
Apr 19, 2023
From: ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 063371/0979 →
Assignment of Assignor's Interest
Jul 29, 2024
From: BABU, YARLAGADDA S.; SHERIDAN, WILLIAM P.
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 068110/0955 →
Assignment of Assignor's Interest
Nov 12, 2024
From: KOTIAN, PRAVIN L.; BABU, YARLAGADDA S.; ZHANG, WEIHE; LU, PENG-CHENG
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 069233/0745 →
Assignment of Assignor's Interest
Jun 11, 2025
From: KOTIAN, PRAVIN L.; BABU, YARLAGADDA S.; WU, MINWAN; CHINTAREDDY, VENKAT R.
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 071384/0297 →
Assignment of Assignor's Interest
Jul 2, 2025
From: KOTIAN, PRAVIN L.; BABU, YARLAGADDA S.; ZHANG, WEIHE; LV, WEI
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 071592/0848 →
Assignment of Assignor's Interest
Jul 2, 2025
From: BABU, YARLAGADDA S.; CHEN, XILIN
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 071801/0055 →
Assignment of Assignor's Interest
Jul 22, 2025
From: KOTIAN, PRAVIN L.; BABU, YARLAGADDA S.; KUMAR, V. SATISH; ZHANG, WEIHE
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 072142/0824 →
Assignment of Assignor's Interest
Jul 22, 2025
From: EL-KATTAN, YAHYA; BABU, YARLAGADDA S.
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 071792/0781 →
Assignment of Assignor's Interest
Aug 18, 2025
From: BABU, YARLAGADDA S.; SHERIDAN, WILLIAM P.; THACKRAY, HELEN M.
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 072507/0552 →
Assignment of Assignor's Interest
Sep 5, 2025
From: EL-KATTAN, YAHYA; BABU, YARLAGADDA S.
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 072171/0946 →
Nunc Pro Tunc Assignment
Dec 29, 2025
From: BABU, YARLAGADDA
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 073326/0400 →
Assignment of Assignor's Interest
Dec 29, 2025
From: CLEARSIDE BIOMEDICAL, INC.
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 073326/0737 →
Assignment of Assignor's Interest
Dec 29, 2025
From: KANSARA, VIRAL; MCELHENY, RICK
To: CLEARSIDE BIOMEDICAL, INC.
Reel/Frame 073326/0670 →
Assignment of Assignor's Interest
Jan 12, 2026
From: EL-KATTAN, YAHYA; BABU, YARLAGADDA S.
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 073440/0481 →